Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SETBP1 mutation analysis in 944 patients with MDS and AML.
Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganser A, Heuser M. Thol F, et al. Among authors: platzbecker u. Leukemia. 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7. Leukemia. 2013. PMID: 23648668 No abstract available.
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Leukemia. 2006 Apr;20(4):707-14. doi: 10.1038/sj.leu.2404143. Leukemia. 2006. PMID: 16482208 Clinical Trial.
Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation.
Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M. Bornhauser M, et al. Among authors: platzbecker u. Leukemia. 2006 Nov;20(11):2055-7. doi: 10.1038/sj.leu.2404383. Epub 2006 Aug 31. Leukemia. 2006. PMID: 16990776 No abstract available.
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Platzbecker U, et al. Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25. doi: 10.1016/j.bbmt.2008.08.006. Biol Blood Marrow Transplant. 2008. PMID: 18940675 Free PMC article. Clinical Trial.
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, Stoehlmacher J, Schetelig J, Thiede C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Biol Blood Marrow Transplant. 2009 Jan;15(1):101-8. doi: 10.1016/j.bbmt.2008.11.004. Biol Blood Marrow Transplant. 2009. PMID: 19135948 Free article. Clinical Trial.
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G. Czibere A, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2010 May;45(5):872-6. doi: 10.1038/bmt.2009.266. Epub 2009 Oct 12. Bone Marrow Transplant. 2010. PMID: 19820729
602 results